Moteur de recherche d’entreprises européennes
Financement de l’UE (5 996 590 €) : MEFISTO - Échafaudage méniscale fonctionnalisé pour prévenir l’apparition de l’arthrose du genou après une méniscectomie Hor18/03/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
MEFISTO - Échafaudage méniscale fonctionnalisé pour prévenir l’apparition de l’arthrose du genou après une méniscectomie
MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy knee osteoarthritis (OA) in Europe. Morphological profiling will identify the population of patients who, after meniscal resection, are at higher risk of early compartment degeneration, providing a personalized approach for the patient. The two different reconstructive strategies are: i) a controlled vascularized bioactive biodegradable meniscal scaffold, which will regenerate the native meniscus. This strategy will address younger patients with early osteoarthritic changes. ii) a bioactive non-biodegradable meniscal prosthesis, which will act as a mechanical unloading device and a drug delivery system, with the capacity to modulate the inflammatory environment. This strategy will address patients with advanced OA. A socio-economic analysis of the efficacy of existing meniscal substitutes will complete the project. This analysis is of vital importance for the European healthcare system, as it will provide a clear understanding of the costs and benefits of current clinical practice and predict the impact of the two new interventions. The technological innovation lies in the development of biologically active functionalized nanobiomaterials that can interact with the surrounding articular tissues. The biodegradable scaffold will promote revascularization in the peripheral zone, while leaving the inner zone avascular, reflecting the native meniscal tissue and functionalization with drug delivery micro/nanoparticles of the non-biodegradable device will provide modulation of inflammation. The impact is expected to be significant as so many patients have undergone or will undergo meniscectomy. The interventions developed in MEFISTO will prevent these patients from receiving joint-sacrificing procedures such as metal prosthesis whilst reducing the social burden, associated costs and high levels of morbidity resulting from OA.
| Active Implants (Israel) Ltd. | 0,00 € |
| Active Implants B.V. | 802 763 € |
| AIM GmbH - Assessment IN Medicine Research AND Consulting | 248 125 € |
| Consiglio Nazionale Delle Ricerche | 461 875 € |
| Etablissement Francais du Sang | 216 875 € |
| Geistlich Biomaterials Vertriebsgesellschaft mbH | 361 250 € |
| Geistlich Pharma AG | 0,00 € |
| Klinikum DER Universitaet Regensburg | 543 750 € |
| Orthokey Italia Srl | 253 125 € |
| Sciprom Sàrl | 320 000 € |
| Tissue Click Ltd. | 401 250 € |
| Universidad de Santiago de Compostela | 482 198 € |
| Universita Humanitas | 847 375 € |
| Universitair Medisch Centrum Utrecht | 559 443 € |
| Universiteit Antwerpen | 498 563 € |
https://cordis.europa.eu/project/id/814444
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
